Psychedelics for major depression-From controlled research settings into broader clinical use.
Cell Rep Med September 1, 2025 Mihai Avram, Stefan Borgwardt
Recent phase 2 randomized controlled trials indicate that psychedelics can reduce symptoms of depression, and phase 3 trials are now in progress. The biological and psychological processes behind these effects—including receptor activity, subjective experiences, and the role of context—are not yet fully explained. The authors review current clinical findings and mechanistic insights, then suggest directions for further investigation.